NASDAQ:SRDX Surmodics (SRDX) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free SRDX Stock Alerts $26.17 +0.10 (+0.38%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$25.22▼$26.2250-Day Range$25.39▼$33.2652-Week Range$16.79▼$39.41Volume31,837 shsAverage Volume58,315 shsMarket Capitalization$372.66 millionP/E Ratio68.87Dividend YieldN/APrice Target$59.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Surmodics alerts: Email Address Surmodics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside128.0% Upside$59.00 Price TargetShort InterestBearish3.47% of Float Sold ShortDividend StrengthN/ASustainability-2.52Upright™ Environmental ScoreNews Sentiment0.12Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.90) to ($0.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.23 out of 5 starsMedical Sector168th out of 907 stocksSurgical & Medical Instruments Industry28th out of 96 stocks 3.5 Analyst's Opinion Consensus RatingSurmodics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSurmodics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.47% of the float of Surmodics has been sold short.Short Interest Ratio / Days to CoverSurmodics has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Surmodics has recently increased by 5.79%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSurmodics does not currently pay a dividend.Dividend GrowthSurmodics does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSurmodics has received a 38.03% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic antigens", " Coatings for drug delivery devices", and "Medical equipment engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Surmodics is -2.52. Previous Next 2.3 News and Social Media Coverage News SentimentSurmodics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Surmodics this week, compared to 2 articles on an average week.Search Interest1 people have searched for SRDX on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Surmodics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Surmodics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.90% of the stock of Surmodics is held by insiders.Percentage Held by Institutions96.63% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Surmodics are expected to grow in the coming year, from ($0.90) to ($0.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surmodics is 68.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Surmodics is 68.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 201.39.Price to Book Value per Share RatioSurmodics has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Surmodics Stock (NASDAQ:SRDX)Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.Read More SRDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRDX Stock News HeadlinesApril 24, 2024 | americanbankingnews.comSurmodics (NASDAQ:SRDX) Downgraded by StockNews.com to BuyApril 19, 2024 | businesswire.comSurmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 17, 2024 | finance.yahoo.comWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowApril 17, 2024 | americanbankingnews.comSurmodics (NASDAQ:SRDX) Upgraded by StockNews.com to "Strong-Buy"April 13, 2024 | finance.yahoo.comInvestors in Surmodics (NASDAQ:SRDX) have unfortunately lost 54% over the last three yearsApril 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)March 23, 2024 | finance.yahoo.comShould You Think About Buying Surmodics, Inc. (NASDAQ:SRDX) Now?April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.March 2, 2024 | finance.yahoo.comAre Surmodics, Inc.'s (NASDAQ:SRDX) Mixed Financials Driving The Negative Sentiment?February 27, 2024 | businesswire.comSurmodics to Participate in Upcoming Investor Conferences in March and AprilFebruary 6, 2024 | ca.finance.yahoo.comSYK Jun 2024 290.000 putFebruary 4, 2024 | finance.yahoo.comHere's What Analysts Are Forecasting For Surmodics, Inc. (NASDAQ:SRDX) After Its First-Quarter ResultsFebruary 2, 2024 | finance.yahoo.comHere's Why Shareholders May Want To Be Cautious With Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Pay PacketFebruary 2, 2024 | finance.yahoo.comSurmodics, Inc. (NASDAQ:SRDX) Q1 2024 Earnings Call TranscriptFebruary 2, 2024 | finance.yahoo.comSurmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 ViewFebruary 1, 2024 | marketwatch.comSurmodics Shares Decline 10% on Investors' Lofty Expectations for SurVeilFebruary 1, 2024 | finance.yahoo.comSurmodics Inc (SRDX) Posts Revenue Growth and Narrows Net Loss in Q1 Fiscal 2024February 1, 2024 | msn.comSurmodics beats top-line and bottom-line estimates; updates FY24 outlookFebruary 1, 2024 | finance.yahoo.comSurModics (SRDX) Reports Break-Even Earnings for Q1February 1, 2024 | finance.yahoo.comSurModics (SRDX) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesFebruary 1, 2024 | finance.yahoo.comSurmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial GuidanceJanuary 31, 2024 | benzinga.comA Preview Of Surmodics's EarningsJanuary 22, 2024 | finance.yahoo.comSurmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the KneeJanuary 16, 2024 | finance.yahoo.comSurmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1January 10, 2024 | finance.yahoo.comReturns Are Gaining Momentum At Surmodics (NASDAQ:SRDX)January 8, 2024 | finance.yahoo.comSurmodics, Inc. (SRDX) Stock Historical Prices & Data - Yahoo FinanceSee More Headlines Receive SRDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/06/2023Today4/25/2024Next Earnings (Confirmed)5/01/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:SRDX CUSIP86887310 CIK924717 Webwww.surmodics.com Phone(952) 500-7000Fax952-500-7001Employees376Year Founded1979Price Target and Rating Average Stock Price Target$59.00 High Stock Price Target$71.00 Low Stock Price Target$47.00 Potential Upside/Downside+126.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.38 Trailing P/E Ratio68.61 Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,540,000.00 Net Margins3.99% Pretax Margin7.07% Return on Equity8.06% Return on Assets5.11% Debt Debt-to-Equity Ratio0.24 Current Ratio4.84 Quick Ratio3.97 Sales & Book Value Annual Sales$132.58 million Price / Sales2.80 Cash Flow$0.76 per share Price / Cash Flow34.33 Book Value$8.48 per share Price / Book3.07Miscellaneous Outstanding Shares14,240,000Free Float12,969,000Market Cap$371.24 million OptionableOptionable Beta1.01 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Gary R. Maharaj (Age 61)CEO, President & Director Comp: $1.33MMr. Timothy J. Arens (Age 57)Senior VP of Finance & Information Technology and CFO Comp: $645.3kMr. Gordon S. Weber (Age 61)Senior VP of Legal, General Counsel & Secretary Comp: $602.84kMr. Charles W. Olson (Age 60)Senior VP & President of Medical Device Coatings Comp: $618.47kMs. Teryl L. W. Sides (Age 54)Senior VP & President of Vascular Interventions Comp: $744.38kMr. John D. Manders (Age 43)Corporate Controller, VP of Finance & Principal Accounting Officer Mr. Joseph J. Stich (Age 59)Senior VP of Human Resources & President of In Vitro Diagnostics Comp: $570.92kMore ExecutivesKey CompetitorsOrthofix MedicalNASDAQ:OFIXAngioDynamicsNASDAQ:ANGOAccurayNASDAQ:ARAYCytosorbentsNASDAQ:CTSOIntersect ENTNASDAQ:XENTView All CompetitorsInstitutional OwnershipMesirow Financial Investment Management Inc.Bought 7,614 shares on 4/19/2024Ownership: 0.053%Salem Investment Counselors Inc.Sold 8,940 shares on 4/11/2024Ownership: 0.850%Quadrature Capital LtdBought 13,856 shares on 3/25/2024Ownership: 0.097%Teton Advisors Inc.Sold 12,900 shares on 2/13/2024Ownership: 0.235%Hillsdale Investment Management Inc.Bought 620 shares on 2/9/2024Ownership: 0.032%View All Institutional Transactions SRDX Stock Analysis - Frequently Asked Questions Should I buy or sell Surmodics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRDX shares. View SRDX analyst ratings or view top-rated stocks. What is Surmodics' stock price target for 2024? 2 analysts have issued 1 year price objectives for Surmodics' shares. Their SRDX share price targets range from $47.00 to $71.00. On average, they expect the company's share price to reach $59.00 in the next year. This suggests a possible upside of 128.0% from the stock's current price. View analysts price targets for SRDX or view top-rated stocks among Wall Street analysts. How have SRDX shares performed in 2024? Surmodics' stock was trading at $36.35 at the beginning of the year. Since then, SRDX shares have decreased by 28.8% and is now trading at $25.88. View the best growth stocks for 2024 here. When is Surmodics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our SRDX earnings forecast. How can I listen to Surmodics' earnings call? Surmodics will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13745933". How were Surmodics' earnings last quarter? Surmodics, Inc. (NASDAQ:SRDX) posted its earnings results on Monday, February, 6th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.13. The firm had revenue of $24.93 million for the quarter, compared to the consensus estimate of $24.19 million. Surmodics had a trailing twelve-month return on equity of 8.06% and a net margin of 3.99%. During the same quarter in the prior year, the company posted ($0.13) EPS. What guidance has Surmodics issued on next quarter's earnings? Surmodics updated its FY 2024 earnings guidance on Thursday, February, 1st. The company provided earnings per share guidance of -1.170--0.870 for the period, compared to the consensus estimate of -1.160. The company issued revenue guidance of $113.0 million-$117.0 million, compared to the consensus revenue estimate of $119.3 million. What is Gary Maharaj's approval rating as Surmodics' CEO? 8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees. What other stocks do shareholders of Surmodics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX). Who are Surmodics' major shareholders? Surmodics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Salem Investment Counselors Inc. (0.85%) and Mesirow Financial Investment Management Inc. (0.05%). Insiders that own company stock include Charles W Olson, Charles W Olson, David Dantzker, Gary R Maharaj, John D Manders, Jose H Bedoya, Joseph J Stich, Joseph J Stich and Ronald B Sr Kalich Sr. View institutional ownership trends. How do I buy shares of Surmodics? Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SRDX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
